Skip to main content
Top
Published in: Immunity & Ageing 1/2008

Open Access 01-12-2008 | Short report

Smoking, health and ageing

Authors: Vittorio Nicita-Mauro, Giorgio Basile, Giuseppe Maltese, Claudio Nicita-Mauro, Sebastiano Gangemi, Calogero Caruso

Published in: Immunity & Ageing | Issue 1/2008

Login to get access

Abstract

On March 19, 2008 a Symposium on Pathophysiology of Ageing and Age-Related diseases was held in Palermo, Italy. Here, the lecture of V. Nicita-Mauro on Smoking, health and ageing is summarized. Smoking represents an important ageing accelerator, both directly by triggering ana inflammatory responses, and indirectly by favoring the occurrence of several diseases where smoking is a recognized risk factor. Hence, non-smokers can delay the appearance of diseases and of ageing process, so attaining longevity.
Appendix
Available only for authorised users
Literature
1.
go back to reference Vasto S, Candore G, Balistreri CR, Caruso M, Colonna-Romano G, Grimaldi MP, Listi F, Nuzzo D, Lio D, Caruso C: Inflammatory networks in ageing, age-related diseases and longevity. Mech Ageing Dev. 2007, 128: 83-91. 10.1016/j.mad.2006.11.015.CrossRefPubMed Vasto S, Candore G, Balistreri CR, Caruso M, Colonna-Romano G, Grimaldi MP, Listi F, Nuzzo D, Lio D, Caruso C: Inflammatory networks in ageing, age-related diseases and longevity. Mech Ageing Dev. 2007, 128: 83-91. 10.1016/j.mad.2006.11.015.CrossRefPubMed
2.
go back to reference Nicita-Mauro V, Lo Balbo C, Mento A, Nicita-Mauro C, Maltese G, Basile G: Smoking, aging and the centenarians. Exp Gerontol. 2008, 43: 95-101. 10.1016/j.exger.2007.06.011.CrossRefPubMed Nicita-Mauro V, Lo Balbo C, Mento A, Nicita-Mauro C, Maltese G, Basile G: Smoking, aging and the centenarians. Exp Gerontol. 2008, 43: 95-101. 10.1016/j.exger.2007.06.011.CrossRefPubMed
3.
go back to reference Crowley Weber CL, Dvorakova K, Crowley C, Bernstein H, Bernstein C, Garewal H, Payne CM: Nicotine increases oxidative stress, activates NF-kappaB and GRP78, induces apoptosis and sensitizes cells to genotoxic/xenobiotic stresses by a multiple stress inducer, deoxycholate: relevance to colon carcinogenesis. Chem Biol Interact. 2003, 145: 53-66. 10.1016/S0009-2797(02)00162-X.CrossRefPubMed Crowley Weber CL, Dvorakova K, Crowley C, Bernstein H, Bernstein C, Garewal H, Payne CM: Nicotine increases oxidative stress, activates NF-kappaB and GRP78, induces apoptosis and sensitizes cells to genotoxic/xenobiotic stresses by a multiple stress inducer, deoxycholate: relevance to colon carcinogenesis. Chem Biol Interact. 2003, 145: 53-66. 10.1016/S0009-2797(02)00162-X.CrossRefPubMed
4.
go back to reference Polidori MC, Mecocci P, Stahl W, Sies H: Cigarette smoking cessation increases plasma levels of several antioxidant micronutrients and improves resistance towards oxidative challenge. Br J Nutr. 2003, 90: 147-150. 10.1079/BJN2003890.CrossRefPubMed Polidori MC, Mecocci P, Stahl W, Sies H: Cigarette smoking cessation increases plasma levels of several antioxidant micronutrients and improves resistance towards oxidative challenge. Br J Nutr. 2003, 90: 147-150. 10.1079/BJN2003890.CrossRefPubMed
5.
go back to reference Ueta E, Tadokoro Y, Yamamoto T, Yamane C, Suzuki E, Nanba E, Otsuka Y, Kurata T: The effect of cigarette smoke exposure and ascorbic Acid intake on gene expression of antioxidant enzymes and other related enzymes in the livers and lungs of shionogi rats with osteogenic disorders. Toxicol Sci. 2003, 73: 339-347. 10.1093/toxsci/kfg082.CrossRefPubMed Ueta E, Tadokoro Y, Yamamoto T, Yamane C, Suzuki E, Nanba E, Otsuka Y, Kurata T: The effect of cigarette smoke exposure and ascorbic Acid intake on gene expression of antioxidant enzymes and other related enzymes in the livers and lungs of shionogi rats with osteogenic disorders. Toxicol Sci. 2003, 73: 339-347. 10.1093/toxsci/kfg082.CrossRefPubMed
6.
go back to reference Antoniades C, Tousoulis D, Tentolouris C, Tsioufis C, Toutouza M, Toutouzas P, Stefanadis C: Effects of antioxidant vitamins C and E on endothelial function and thrombosis/fibrinolysis system in smokers. Thromb Haemost. 2003, 89: 990-995.PubMed Antoniades C, Tousoulis D, Tentolouris C, Tsioufis C, Toutouza M, Toutouzas P, Stefanadis C: Effects of antioxidant vitamins C and E on endothelial function and thrombosis/fibrinolysis system in smokers. Thromb Haemost. 2003, 89: 990-995.PubMed
7.
go back to reference Juan DDHD, Li J, Wang JYJ, Gao C, Chen M: A 2-year follow-up study of cigarette smoking and risk of dementia. Eur J Neurol. 2004, 11: 277-282. 10.1046/j.1468-1331.2003.00779.x.CrossRefPubMed Juan DDHD, Li J, Wang JYJ, Gao C, Chen M: A 2-year follow-up study of cigarette smoking and risk of dementia. Eur J Neurol. 2004, 11: 277-282. 10.1046/j.1468-1331.2003.00779.x.CrossRefPubMed
8.
go back to reference Moria M, Busquets X, Pons J, Sauleda J, MacNee W, Agusti AGN: Telomere Shortening in smokers with and without COPD. Eur Respir J. 2006, 27: 525-528. 10.1183/09031936.06.00087005.CrossRef Moria M, Busquets X, Pons J, Sauleda J, MacNee W, Agusti AGN: Telomere Shortening in smokers with and without COPD. Eur Respir J. 2006, 27: 525-528. 10.1183/09031936.06.00087005.CrossRef
9.
go back to reference Candore G, Balistreri CR, Colonna-Romano G, Grimaldi MP, Lio D, Listi' F, Scola L, Vasto S, Caruso C: Immunosenescence and anti-immunosenescence therapies: the case of probiotics. Rejuvenation Res. 2008, 11: 425-32. 10.1089/rej.2008.0662.CrossRefPubMed Candore G, Balistreri CR, Colonna-Romano G, Grimaldi MP, Lio D, Listi' F, Scola L, Vasto S, Caruso C: Immunosenescence and anti-immunosenescence therapies: the case of probiotics. Rejuvenation Res. 2008, 11: 425-32. 10.1089/rej.2008.0662.CrossRefPubMed
10.
go back to reference Anstey KJ, von Sanden C, Salim A, O'Kearney R: Smoking as a Risk Factor for Dementia and Cognitive Decline: A Meta-Analysis of Prospective Studies. Am J Epidemiol. 2007, 166: 367-378. 10.1093/aje/kwm116.CrossRefPubMed Anstey KJ, von Sanden C, Salim A, O'Kearney R: Smoking as a Risk Factor for Dementia and Cognitive Decline: A Meta-Analysis of Prospective Studies. Am J Epidemiol. 2007, 166: 367-378. 10.1093/aje/kwm116.CrossRefPubMed
11.
go back to reference Riggs JE: Smoking and Alzheimer 2000's disease: protective effect or differential survival bias?. Lancet. 1993, 342: 793-794. 10.1016/0140-6736(93)91547-Y.CrossRefPubMed Riggs JE: Smoking and Alzheimer 2000's disease: protective effect or differential survival bias?. Lancet. 1993, 342: 793-794. 10.1016/0140-6736(93)91547-Y.CrossRefPubMed
12.
go back to reference Elrod K, Buccafusco JJ, Jackson WJ: Nicotine enhances delayed matching-to-sample performance by primates. Life Sci. 1988, 43: 277-87. 10.1016/0024-3205(88)90318-9.CrossRefPubMed Elrod K, Buccafusco JJ, Jackson WJ: Nicotine enhances delayed matching-to-sample performance by primates. Life Sci. 1988, 43: 277-87. 10.1016/0024-3205(88)90318-9.CrossRefPubMed
13.
go back to reference Skoog L: Status of risk factors for vascular dementia. Neuroepidemiology. 1998, 17: 2-9. 10.1159/000026147.CrossRefPubMed Skoog L: Status of risk factors for vascular dementia. Neuroepidemiology. 1998, 17: 2-9. 10.1159/000026147.CrossRefPubMed
14.
go back to reference Esiri M, Nagy Z, Smith MZ, Barnetson L, Smith AD: Cerebrovascular disease and threshold for dementia in the early stages of Alzheimer's disease. Lancet. 1999, 354: 919-920. 10.1016/S0140-6736(99)02355-7.CrossRefPubMed Esiri M, Nagy Z, Smith MZ, Barnetson L, Smith AD: Cerebrovascular disease and threshold for dementia in the early stages of Alzheimer's disease. Lancet. 1999, 354: 919-920. 10.1016/S0140-6736(99)02355-7.CrossRefPubMed
15.
go back to reference Nicita-Mauro V: Smoking, calcium, calcium antagonists, and aging. Exp Gerontol. 1990, 25: 393-399. 10.1016/0531-5565(90)90077-F.CrossRefPubMed Nicita-Mauro V: Smoking, calcium, calcium antagonists, and aging. Exp Gerontol. 1990, 25: 393-399. 10.1016/0531-5565(90)90077-F.CrossRefPubMed
16.
go back to reference Hardoon SL, Whincup PH, Lennon LT, Wannamethee SG, Capewell S, Morris RW: How Much of the Recent Decline in the Incidence of Myocardial Infarction in British Men Can Be Explained by Changes in Cardiovascular Risk Factors?: Evidence From a Prospective Population-Based Study. Circulation. 2008, 117: 598-604. 10.1161/CIRCULATIONAHA.107.705947.PubMedCentralCrossRefPubMed Hardoon SL, Whincup PH, Lennon LT, Wannamethee SG, Capewell S, Morris RW: How Much of the Recent Decline in the Incidence of Myocardial Infarction in British Men Can Be Explained by Changes in Cardiovascular Risk Factors?: Evidence From a Prospective Population-Based Study. Circulation. 2008, 117: 598-604. 10.1161/CIRCULATIONAHA.107.705947.PubMedCentralCrossRefPubMed
17.
go back to reference Jensen MK, Chiuve SE, Rimm EB, Dethlefsen C, Tjønneland A, Joensen AM, Overvad K: Obesity, Behavioral Lifestyle Factors, and Risk of Acute Coronary Events. Circulation. 2008, 117: 3062-3069. 10.1161/CIRCULATIONAHA.107.759951.CrossRefPubMed Jensen MK, Chiuve SE, Rimm EB, Dethlefsen C, Tjønneland A, Joensen AM, Overvad K: Obesity, Behavioral Lifestyle Factors, and Risk of Acute Coronary Events. Circulation. 2008, 117: 3062-3069. 10.1161/CIRCULATIONAHA.107.759951.CrossRefPubMed
18.
go back to reference Doll R, Peto R, Boreham J, Sutherland I: Mortality in relation to smoking: 50 years' observations on male British doctors. Br Med J. 2004, 328: 1519-15. 10.1136/bmj.38142.554479.AE.CrossRef Doll R, Peto R, Boreham J, Sutherland I: Mortality in relation to smoking: 50 years' observations on male British doctors. Br Med J. 2004, 328: 1519-15. 10.1136/bmj.38142.554479.AE.CrossRef
19.
go back to reference Yates LB, Djousse L, Kurth T, Buring JE, Gaziano JM: Exceptional Longevity in men. Arch Intern Med. 2008, 168: 284-290. 10.1001/archinternmed.2007.77.CrossRefPubMed Yates LB, Djousse L, Kurth T, Buring JE, Gaziano JM: Exceptional Longevity in men. Arch Intern Med. 2008, 168: 284-290. 10.1001/archinternmed.2007.77.CrossRefPubMed
20.
go back to reference Bratzler DW, Oehlert WH, Austelle A: Smoking in the elderly. It's never too late to quit. J Okla State Med Assoc. 2002, 95: 185-191.PubMed Bratzler DW, Oehlert WH, Austelle A: Smoking in the elderly. It's never too late to quit. J Okla State Med Assoc. 2002, 95: 185-191.PubMed
21.
go back to reference Gourlay SG, Benowitz NL: The benefits of stopping smoking and the role of nicotine replacement therapy in older patients. Drugs Aging. 1996, 9: 8-23. 10.2165/00002512-199609010-00002.CrossRefPubMed Gourlay SG, Benowitz NL: The benefits of stopping smoking and the role of nicotine replacement therapy in older patients. Drugs Aging. 1996, 9: 8-23. 10.2165/00002512-199609010-00002.CrossRefPubMed
22.
go back to reference Jorenby DE, Leischow SJ, Nides MA, Rennard SI, Johnston JA, Hughes AR, Smith SS, Muramoto ML, Daughton DM, Doan K, Fiore MC, Baker TB: A controlled trial of sustainedrelease bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med. 1999, 340: 685-691. 10.1056/NEJM199903043400903.CrossRefPubMed Jorenby DE, Leischow SJ, Nides MA, Rennard SI, Johnston JA, Hughes AR, Smith SS, Muramoto ML, Daughton DM, Doan K, Fiore MC, Baker TB: A controlled trial of sustainedrelease bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med. 1999, 340: 685-691. 10.1056/NEJM199903043400903.CrossRefPubMed
23.
go back to reference Tonstad S, Tønnesen P, Hajek P, William KE, Billing CB, Reeves KR: Varenicline Phase 3 Study Group. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA. 2006, 296: 64-71. 10.1001/jama.296.1.64.CrossRefPubMed Tonstad S, Tønnesen P, Hajek P, William KE, Billing CB, Reeves KR: Varenicline Phase 3 Study Group. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA. 2006, 296: 64-71. 10.1001/jama.296.1.64.CrossRefPubMed
24.
go back to reference Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, William KE, Billing CB, Gong J, Reeves KR: Varenicline Phase 3 Study Group. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA. 2006, 296: 56-63. 10.1001/jama.296.1.56.CrossRefPubMed Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, William KE, Billing CB, Gong J, Reeves KR: Varenicline Phase 3 Study Group. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA. 2006, 296: 56-63. 10.1001/jama.296.1.56.CrossRefPubMed
25.
go back to reference Taylor Hays J, Ebbert JO, Sood A: Efficacy and safety of varenicline for smoking cessation. AJM. 2008, 121: S32-S42. 10.1016/j.amjmed.2008.01.017.CrossRef Taylor Hays J, Ebbert JO, Sood A: Efficacy and safety of varenicline for smoking cessation. AJM. 2008, 121: S32-S42. 10.1016/j.amjmed.2008.01.017.CrossRef
26.
go back to reference Nides M: Update on pharmacological options for smoking cessation treatment. AJM. 2008, 121: S20-S31. 10.1016/j.amjmed.2008.01.016.CrossRef Nides M: Update on pharmacological options for smoking cessation treatment. AJM. 2008, 121: S20-S31. 10.1016/j.amjmed.2008.01.016.CrossRef
Metadata
Title
Smoking, health and ageing
Authors
Vittorio Nicita-Mauro
Giorgio Basile
Giuseppe Maltese
Claudio Nicita-Mauro
Sebastiano Gangemi
Calogero Caruso
Publication date
01-12-2008
Publisher
BioMed Central
Published in
Immunity & Ageing / Issue 1/2008
Electronic ISSN: 1742-4933
DOI
https://doi.org/10.1186/1742-4933-5-10

Other articles of this Issue 1/2008

Immunity & Ageing 1/2008 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.